{"id":21013,"date":"2025-01-28T18:40:34","date_gmt":"2025-01-28T19:40:34","guid":{"rendered":"http:\/\/medexperts.pro\/?p=21013"},"modified":"2025-01-28T20:29:01","modified_gmt":"2025-01-28T20:29:01","slug":"f-d-a-approves-ozempic-to-treat-kidney-disease","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=21013","title":{"rendered":"F.D.A. Approves Ozempic to Treat Kidney Disease"},"content":{"rendered":"
<\/div>\n

The decision will further broaden the use of the blockbuster drug.<\/p>\n

\n
\n
\n

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both type 2 diabetes and chronic kidney disease.<\/p>\n

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than one in seven U.S. adults. The medication can lower the chance that patients with both conditions will undergo worsening kidney disease, kidney failure and death from cardiovascular issues.<\/p>\n

\u201cOver the last 20 years, it\u2019s been an area where researchers tried hard but delivered very little,\u201d said Dr. Stephen Gough, senior vice president of global medical affairs at Novo Nordisk, the company that makes Ozempic. \u201cTo have something new like this is really exciting, and offers promise to patients,\u201d he said.<\/p>\n

Ozempic is already approved to treat Type 2 diabetes and to lower the risk of major cardiovascular events in adults with diabetes and a history of heart disease. The F.D.A. based its decision to expand the approved uses of Ozempic on research<\/a> showing that people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower likelihood of experiencing a complication, like requiring dialysis or a transplant, compared to people who took a placebo. They also had slower rates of kidney decline and were less likely to die from cardiovascular problems.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

\u201cThe more we can delay the decline in kidney function, the better,\u201d said Dr. Melanie Hoenig, a nephrologist at Beth Israel Deaconess Medical Center in Boston. Dr. Hoenig said she already prescribes Ozempic to some of her patients.<\/p>\n

Doctors have long expressed frustration with just how few options there are for treatment. Many patients take medications to lower blood pressure, blood sugar and cholesterol, which tend to be elevated in people with chronic kidney disease. Patients also sometimes take drugs to alleviate swelling that occurs when the kidneys can\u2019t properly filter fluid, as well as medications to manage iron, calcium and vitamin D levels.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The decision will further broaden the use of the blockbuster drug.The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both type 2 diabetes and chronic kidney disease.Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than one in seven U.S. adults. The medication can lower the chance that patients with both conditions will undergo worsening kidney disease, kidney failure and death from cardiovascular issues.\u201cOver the last 20 years, it\u2019s been an area where researchers tried hard but delivered very little,\u201d said Dr. Stephen Gough, senior vice president of global medical affairs at Novo Nordisk, the company that makes Ozempic. \u201cTo have something new like this is really exciting, and offers promise to patients,\u201d he said.Ozempic is already approved to treat Type 2 diabetes and to lower the risk of major cardiovascular events in adults with diabetes and a history of heart disease. The F.D.A. based its decision to expand the approved uses of Ozempic on research showing that people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower likelihood of experiencing a complication, like requiring dialysis or a transplant, compared to people who took a placebo. They also had slower rates of kidney decline and were less likely to die from cardiovascular problems.\u201cThe more we can delay the decline in kidney function, the better,\u201d said Dr. Melanie Hoenig, a nephrologist at Beth Israel Deaconess Medical Center in Boston. Dr. Hoenig said she already prescribes Ozempic to some of her patients.Doctors have long expressed frustration with just how few options there are for treatment. Many patients take medications to lower blood pressure, blood sugar and cholesterol, which tend to be elevated in people with chronic kidney disease. Patients also sometimes take drugs to alleviate swelling that occurs when the kidneys can\u2019t properly filter fluid, as well as medications to manage iron, calcium and vitamin D levels.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":21015,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-21013","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lifestyle"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21013"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21013\/revisions"}],"predecessor-version":[{"id":21016,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21013\/revisions\/21016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/21015"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}